1-20 of 29824
Sort by
Journal
Issue cover
Inflammatory Bowel Diseases brings the most current information in clinical and basic sciences to physicians caring for patients with inflammatory bowel diseases, and investigators performing research in IBD and related fields.
Journal
Issue cover
Crohn's & Colitis 360 is an official publication of the Crohn's & Colitis Foundation. The online-only, open access journal publishes content that engages, informs, and catalyzes dialogue on state-of-the-art comprehensive care for patients with inflammatory bowel disease.
Journal Article
Cong Dai and Yu-hong Huang
Inflammatory Bowel Diseases, izaf080, https://doi.org/10.1093/ibd/izaf080
Published: 26 April 2025
Journal Article
Simen Hyll Hansen and others
Inflammatory Bowel Diseases, izaf060, https://doi.org/10.1093/ibd/izaf060
Published: 25 April 2025
Image
Published: 25 April 2025
Figure 3. Kaplan–Meier curves (unadjusted) showing time from index date (statin initiation) to any inflammatory bowel disease (IBD)-related disease flare in patients with ulcerative colitis (UC) and Crohn’s disease (CD) comparing statin users and non-users. Number of events is shown in the parenthesis. (Log-r
Image
Published: 25 April 2025
Figure 2. Alternative severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) entry pathway molecules are not significantly modulated in the intestinal mucosa of inflammatory bowel disease (IBD) patients. The mRNA expression levels of AGTR1 (A) and ADAM17 (B) were evaluated by RT-PCR, comparing results b
Image
Published: 25 April 2025
Figure 4. Increased circulating mannose-binding lectin (MBL) levels in inflammatory bowel disease (IBD) patients compared to healthy individuals. Circulating MBL levels were measured in total IBD (A), Crohn’s disease (CD), or ulcerative colitis (UC) (B), and patients were stratified by treatment, compared to
Image
Published: 25 April 2025
Figure 2. Kaplan–Meier curves illustrating relapse-related drug discontinuation-free survival among 112 patients with Crohn’s disease according to the achievement of transmural healing, biochemical remission (reflecting mucosal healing), intestinal ultrasound healing (IUS), or no healing.
Image
Published: 25 April 2025
Figure 3. Comparison of patients’ acceptability between intestinal ultrasound and fecal calprotectin testing in 112 patients with Crohn’s disease.
Image
Published: 25 April 2025
Figure 1. A , Beta diversity (Bray-Curtis dissimilarity) plot showing the microbial composition of all participants, colored by disease category (purple = Crohn’s disease [CD], blue = ulcerative colitis [UC], green = symptomatic controls [SC], and gray = miscellaneous categories [IBD-U, suspected IBD colon or
Image
Published: 25 April 2025
Figure 2. A, Alpha diversity plots showing that CD and UC have a reduced diversity as estimated by the Shannon diversity index, compared to symptomatic and healthy controls (SC and HC, respectively). Barplot demonstrates effect size and P -value of alpha diversity differences after correcting for age, sex,
Journal Article
Julie Huet and others
Inflammatory Bowel Diseases, izaf068, https://doi.org/10.1093/ibd/izaf068
Published: 25 April 2025
Image
Published: 25 April 2025
Figure 1. Kaplan–Meier curves (unadjusted) showing time from index date (statin initiation) to any inflammatory bowel disease (IBD)-related surgical event in patients with ulcerative colitis (UC) and Crohn’s disease (CD) comparing statin users and non-users. Number of events is shown in the parenthesis. (Log-
Image
Published: 25 April 2025
Figure 2. Kaplan–Meier curves (unadjusted) showing time from index date (statin initiation) to any inflammatory bowel disease (IBD)-related hospitalization in patients with ulcerative colitis (UC) and Crohn’s disease (CD) comparing statin users and non-users. Number of events is shown in the parenthesis. (Log
Image
Published: 25 April 2025
Figure 3. Impact of biologic medications on circulating sACE2 levels in inflammatory bowel disease (IBD) patients. Serum concentration of sACE2 was evaluated in (A) total IBD patients, (B) Crohn’s disease (CD) or ulcerative colitis (UC) patients versus healthy donors (HDs), (C) IBD patients stratified by medi
Image
Published: 25 April 2025
Figure 3. Serum metabolites are altered in IBD patients with CKD compared to those without CKD. (A) Univariate analysis of untargeted serum metabolomics data comparing IBD patients with CKD ( n  = 23) to IBD patients without CKD ( n  = 31). (B) Principal component analysis (PCA) of untargeted metabolites from
Image
Published: 25 April 2025
Figure 4. A , Alpha diversity plots demonstrating a reduced diversity as measured by the Shannon diversity index in those patients with a future severe disease course in CD and UC, respectively. B, Bar plot showing average numbers of different genera, demonstrating that the major factor affecting the loss o
Image
Published: 25 April 2025
Figure 5. A, B, C, D, AUC curves showing the predictive capacity of 3 different sets of variables for classifying a future severe disease course in CD and UC, respectively. In CD, the variable set “Clinical” scored significantly better than microbiome data ( P  < .0001). The opposite was true in UC, where
Journal Article
Hamed Khalili and others
Inflammatory Bowel Diseases, izaf077, https://doi.org/10.1093/ibd/izaf077
Published: 25 April 2025
Journal Article
Laura Francesca Pisani and others
Inflammatory Bowel Diseases, izaf079, https://doi.org/10.1093/ibd/izaf079
Published: 25 April 2025